Use of an NK-3 receptor antagonist in the treatment of conditions characterised by altered bowel function and/or visceral pain

摘要

The use of compounds of formula (I), including the compound (S)-N-(alpha-ethylbenzyl)-3-hydroxy-2- phenylquinoline-4-carboxamide, as an NK3 antagonist and to treat conditions characterized by altered bowel function and/or visceral pain in humans or non-human mammals. The conditions treated may include irritable bowel syndrome conditions, functional abdominal bloating, functional constipation, functional diarrhea, other bowel conditions and functional abdominal pain.